BofA analyst Greg Harrison downgraded Beam Therapeutics to Neutral from Buy with a $35 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BEAM:
- Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
- Qualcomm downgraded, First Solar upgraded: Wall Street’s top analyst calls
- Beam Therapeutics just downgraded at Jefferies, here’s why
- Beam Therapeutics price target lowered to $26 from $35 at Barclays
- Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results